<VariationArchive VariationID="233164" VariationName="NM_000051.4(ATM):c.9021dup (p.Arg3008fs)" VariationType="Duplication" Accession="VCV000233164" Version="18" RecordType="classified" NumberOfSubmissions="6" NumberOfSubmitters="6" DateLastUpdated="2024-07-29" DateCreated="2016-05-29" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="234427" VariationID="233164">
      <GeneList>
        <Gene Symbol="ATM" FullName="ATM serine/threonine kinase" GeneID="472" HGNC_ID="HGNC:795" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108223067" stop="108369102" display_start="108223067" display_stop="108369102" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="108093558" stop="108239825" display_start="108093558" display_stop="108239825" Strand="+" />
          </Location>
          <OMIM>607585</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ATM">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ATM">No evidence available</Triplosensitivity>
        </Gene>
        <Gene Symbol="C11orf65" FullName="chromosome 11 open reading frame 65" GeneID="160140" HGNC_ID="HGNC:28519" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108308519" stop="108469881" display_start="108308519" display_stop="108469881" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="108253726" stop="108338257" display_start="108253726" display_stop="108338257" Strand="-" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000051.4(ATM):c.9021dup (p.Arg3008fs)</Name>
      <CanonicalSPDI>NC_000011.10:108365356:AA:AAA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>11q22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108365356" stop="108365357" display_start="108365356" display_stop="108365357" variantLength="1" positionVCF="108365356" referenceAlleleVCF="G" alternateAlleleVCF="GA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="108236083" stop="108236084" display_start="108236083" display_stop="108236084" variantLength="1" positionVCF="108236083" referenceAlleleVCF="G" alternateAlleleVCF="GA" />
      </Location>
      <OtherNameList>
        <Name>p.Arg3008Thrfs*55</Name>
      </OtherNameList>
      <ProteinChange>R3008fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000051.3" sequenceAccession="NM_000051" sequenceVersion="3" change="c.9021dupA">
            <Expression>NM_000051.3:c.9021dupA</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.10" sequenceAccession="NC_000011" sequenceVersion="10" change="g.108365358dup" Assembly="GRCh38">
            <Expression>NC_000011.10:g.108365358dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.108236085dup" Assembly="GRCh37">
            <Expression>NC_000011.9:g.108236085dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009830.1" sequenceAccession="NG_009830" sequenceVersion="1" change="g.147527dup">
            <Expression>NG_009830.1:g.147527dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_054724.1" sequenceAccession="NG_054724" sequenceVersion="1" change="g.109476dup">
            <Expression>NG_054724.1:g.109476dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000051.4" sequenceAccession="NM_000051" sequenceVersion="4" change="c.9021dup" MANESelect="true">
            <Expression>NM_000051.4:c.9021dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000042.3" sequenceAccession="NP_000042" sequenceVersion="3" change="p.Arg3008fs">
            <Expression>NP_000042.3:p.Arg3008fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001351834.2" sequenceAccession="NM_001351834" sequenceVersion="2" change="c.9021dup">
            <Expression>NM_001351834.2:c.9021dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001338763.1" sequenceAccession="NP_001338763" sequenceVersion="1" change="p.Arg3008fs">
            <Expression>NP_001338763.1:p.Arg3008fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001330368.2" sequenceAccession="NM_001330368" sequenceVersion="2" change="c.640+20563dup">
            <Expression>NM_001330368.2:c.640+20563dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001351110.2" sequenceAccession="NM_001351110" sequenceVersion="2" change="c.694+20563dup">
            <Expression>NM_001351110.2:c.694+20563dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_135" sequenceAccession="LRG_135">
            <Expression>LRG_135:g.147527dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_135t1" sequenceAccession="LRG_135t1">
            <Expression>LRG_135t1:c.9021dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_135p1" sequenceAccession="LRG_135p1" change="p.Arg3008Thrfs">
            <Expression>LRG_135p1:p.Arg3008Thrfs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA10579336" DB="ClinGen" />
        <XRef Type="rs" ID="876660235" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000051.4(ATM):c.9021dup (p.Arg3008fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000220949" Version="14">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-05-05" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000051.4(ATM):c.9021dup (p.Arg3008fs) AND not provided" Accession="RCV000237011" Version="10">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-04-21" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000051.4(ATM):c.9021dup (p.Arg3008fs) AND Ataxia-telangiectasia syndrome" Accession="RCV000552654" Version="18">
        <ClassifiedConditionList TraitSetID="770">
          <ClassifiedCondition DB="MedGen" ID="C0004135">Ataxia-telangiectasia syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-09-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000051.4(ATM):c.9021dup (p.Arg3008fs) AND Familial cancer of breast" Accession="RCV001823719" Version="11">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-02-06" SubmissionCount="2">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-06" NumberOfSubmissions="6" NumberOfSubmitters="6" DateCreated="2016-05-29" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12552566</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15039971</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15101044</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16266405</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18573109</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21778326</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21965147</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22649200</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25614872</ID>
        </Citation>
        <DescriptionHistory Dated="2022-02-04">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="770" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4635" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Ataxia-telangiectasia, complementation group E</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia-telangiectasia, complementation group D</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AT, COMPLEMENTATION GROUP C</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ATAXIA-TELANGIECTASIA, COMPLEMENTATION GROUP A</ElementValue>
                <XRef Type="Allelic variant" ID="607585.0001" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ATAXIA-TELANGIECTASIA, FRESNO VARIANT</ElementValue>
                <XRef Type="Allelic variant" ID="607585.0014" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia-telangiectasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Louis-Bar syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebello-oculocutaneous telangiectasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Immunodeficiency with ataxia telangiectasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ataxia-telangiectasia syndrome</ElementValue>
                <XRef ID="Ataxia+Telangiectasia/637" DB="Genetic Alliance" />
                <XRef ID="68504005" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">A-T</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATM</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATE</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">AT1</ElementValue>
                <XRef Type="MIM" ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATC</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATA</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATD</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">AT</ElementValue>
                <XRef Type="MIM" ID="208900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Classic ataxia-telangiectasia (A-T) is characterized by progressive cerebellar ataxia beginning between ages one and four years, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections, and an increased risk for malignancy, particularly leukemia and lymphoma. Individuals with A-T are unusually sensitive to ionizing radiation. Non-classic forms of A-T have included adult-onset A-T and A-T with early-onset dystonia.</Attribute>
                <XRef ID="NBK26468" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5862" />
                <XRef ID="5862" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301790</ID>
                <ID Source="BookShelf">NBK26468</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301317</ID>
                <ID Source="BookShelf">NBK1138</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS, 2010">
                <ID Source="PubMed">20050888</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS/ENS, 2014">
                <ID Source="PubMed">24418350</ID>
              </Citation>
              <XRef ID="100" DB="Orphanet" />
              <XRef ID="C0004135" DB="MedGen" />
              <XRef ID="MONDO:0008840" DB="MONDO" />
              <XRef Type="MIM" ID="208900" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="9140936" SubmissionDate="2024-04-22" DateLastUpdated="2024-05-01" DateCreated="2024-05-01">
        <ClinVarSubmissionID localKey="100401686|OMIM:114480" />
        <ClinVarAccession Accession="SCV004933441" DateUpdated="2024-05-01" DateCreated="2024-05-01" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16266405</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25614872</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15039971</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21965147</ID>
          </Citation>
          <Comment>This variant is considered likely pathogenic. This variant creates a frameshift predicted to result in the incorporation of abnormal amino acid sequence into the protein product and abnormal protein elongation. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 16266405, 25614872, 15039971, 21965147].</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="11" alternateAllele="AA" referenceAllele="A" start="108236085" stop="108236085" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">100401686</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14395420</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="513938" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2016-05-29">
        <ClinVarSubmissionID localKey="a898773|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000277484" DateUpdated="2024-05-01" DateCreated="2016-05-29" Type="SCV" Version="7" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16266405</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21778326</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25614872</ID>
          </Citation>
          <Comment>The c.9021dupA pathogenic mutation, located in coding exon 62 of the ATM gene, results from a duplication of A at nucleotide position 9021, causing a translational frameshift with a predicted alternate stop codon (p.R3008Tfs*55). Functional analysis of a lymphoblastoid cell line derived from a compound heterozygous patient with ataxia telangiectasia (AT) suggests this alteration results in deficient ATM protein and a double-strand break repair pattern resembling MRN-complex dysfunction. Authors note that the individual from whom this cell line was derived was older than 60 years with an attenuated or variant form of AT with moderate radiosensitivity, chromosomal instability, and cancer proneness (Keimling M et al. FASEB J. 2011 Nov; 25(11):3849-60). An individual with classic ataxia-telangiectasia was found to be homozygous for this mutation (designated 9021_9022insA, p.Arg3008ThrfsTer54) with the diagnosis confirmed by absence of ATM protein by immunoblotting in lymphoblastoid cell lines and radiosensitivity demonstrated on a colony survival assay (Podralska MJ et al. Mol Genet Genomic Med, 2014 Nov;2:504-11; Mitui M et al. Ann. Hum. Genet. 2005 Nov;69:657-64). In addition to the clinical data presented in the literature, this frameshift occurs near the 3' terminus of ATM and results in the elongation of the protein by 6 amino acids. This mutation alters the sequence of the FATC domain of the ATM protein which has been shown to be necessary for ATM regulation (Jiang XJ et al. Biol. Chem. 2006 Jun;281(23):15741-6). As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000051.3:c.9021dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3412997" SubmissionDate="2021-06-11" DateLastUpdated="2021-06-19" DateCreated="2021-06-19">
        <ClinVarSubmissionID localKey="Db4KrQBSZeoE7-orUyypkaEE7kokG01OFcTIWT25N5M|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001735734" DateUpdated="2021-06-19" DateCreated="2021-06-19" Type="SCV" Version="1" SubmitterName="Color Diagnostics, LLC DBA Color Health" OrgID="505849" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-12-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant inserts 1 nucleotide in exon 63 of the ATM gene, creating a frameshift in the last exon. This variant is also known as c.9021_9022insA in the literature. This variant alters the C-terminus of the TP53 binding domain and FATC domain sequence and is expected to disrupt ATP protein function. This variant has been reported in two biallelic individuals affected with 2 ataxia-telangiectasia (PMID: 21778326, 25614872). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000051.3:c.9021dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>ColorClinVarSubmissionJune2021_SUB9834248</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="562363" SubmissionDate="2019-01-29" DateLastUpdated="2016-07-24" DateCreated="2016-07-24">
        <ClinVarSubmissionID localKey="GDX:666976|Not Provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000293444" DateUpdated="2016-07-24" DateCreated="2016-07-24" Type="SCV" Version="8" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-04-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This duplication of one nucleotide in ATM is denoted c.9021dupA at the cDNA level and p.Arg3008ThrfsX55 (R3008TfsX55) at the protein level. The normal sequence, with the base that is duplicated in brackets, is CTGA[dupA]CGTG. The duplication causes a frameshift, which changes an Arginine to a Threonine at codon 3008, and creates a premature stop codon at position 55 of the new reading frame. Even though this frameshift occurs in the last exon of the gene, and nonsense-mediated decay is not expected to occur, it is significant since the last 49 amino acids are replaced with 54 incorrect amino acids and impacts the FATC domain (Stracker 2013). ATM Arg3008ThrfsX55 has been observed in the homozygous state in a patient with classic Ataxia Telangiectasia, whose lymphoblastoid cell line exhibited radiosensitivity and absence of ATM protein production (Mitui 2005, Podralska 2014). We consider this variant to be pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="11" alternateAllele="AA" referenceAllele="A" start="108236085" stop="108236086" variantLength="2" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000051.3:c.9021dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4063493" SubmissionDate="2022-02-02" DateLastUpdated="2022-02-05" DateCreated="2022-02-05">
        <ClinVarSubmissionID localKey="NM_000051.3: c.9021dup" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002073358" DateUpdated="2022-02-05" DateCreated="2022-02-05" Type="SCV" Version="1" SubmitterName="Molecular Diagnostics Laboratory, M Health Fairview: University of Minnesota" OrgID="506641" OrganizationCategory="laboratory" OrgAbbreviation="UMMC-MDL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-10-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.Arg3008Thrfs*55</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000051.3:c.9021dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11032738</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1214644" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="1471356|MedGen:C0004135" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000622878" DateUpdated="2024-02-20" DateCreated="2017-12-26" Type="SCV" Version="9" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-09-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12552566</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15101044</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18573109</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22649200</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21778326</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21778326</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg3008 amino acid residue in ATM. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12552566, 15101044, 18573109, 22649200). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this frameshift affects ATM function (PMID: 21778326). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. This frameshift has been observed in individual(s) with ataxia-telangiectasia (PMID: 21778326). This variant is not present in population databases (ExAC no frequency). This sequence change results in a frameshift in the ATM gene (p.Arg3008Thrfs*55). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 49 amino acid(s) of the ATM protein and extend the protein by 5 additional amino acid residues.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.108236083_108236084insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0004135" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3412997" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="562363" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9140936" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4063493" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1214644" TraitType="Disease" MappingType="XRef" MappingValue="C0004135" MappingRef="MedGen">
        <MedGen CUI="C0004135" Name="Ataxia-telangiectasia syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="513938" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

